Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that Stuart Gall officially started his role as Chief Executive Officer of the Avingtrans medical and industrial imaging division on 1 January 2026.
Stuart brings a wealth of experience in scaling medical technology companies from innovation to market adoption. He was one of the three founding directors of AIM listed university commercialisation company Fusion IP, that was acquired by IP Group plc for £103m in 2014 and most recently, Chief Executive Officer of AIM listed Intelligent Ultrasound Group plc (AIM: IUG), the medical imaging AI software and simulation vendor, whose AI software operation was sold to GEHC for £40m in 2024 and the remaining simulation business was sold to Surgical Science Sweden AB in February 2025.
Under his leadership, Intelligent Ultrasound transitioned from a university MedTech spin-out to a publicly listed company with global partnerships in both medical education and clinical AI.
At Avingtrans, Stuart will oversee the strategic development and commercialisation of Adaptix and the Magnetica Group. Adaptix is a pioneering low-dose, point-of-care 3D X-ray imaging company, Magnetica is focused on the development of compact, helium-free MRI systems, and Scientific Magnets is a world leader in the design, manufacture and installation of bespoke cryogen-free superconducting magnets.
Stuart Gall commented: “Avingtrans has an exciting portfolio of companies with world-class disruptive technologies that could transform a number of key medical and industrial imaging markets, and I look forward to working with the respective teams to accelerate their commercial adoption and enhance their value to shareholders.”
Steve McQuillan, CEO of Avingtrans plc, added: “We are delighted Stuart has been able to start his role earlier than originally notified to the market and his proven track record in guiding technology companies from early innovation through to commercial success will be invaluable as we continue to build the value of our medical and industrial imaging division.”
